ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
StockNews.AI • 603 days
Low Materiality0/10
Information
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driv...
Original sourceAI Summary
- ANI to acquire Alimera for $5.50 per share in cash, aiming to strengthen Rare Disease segment. - Addition of ILUVIEN® and YUTIQ® will add approximately $105 million in revenues. - Transaction expected to deliver high single-digit to low double-digit accretion in adjusted EPS. Price Impact Rating: Bullish Impact Horizon Rating: Long-term Type: M&A
Market-Moving
- ANI to acquire Alimera for $5.50 per share in cash, aiming to strengthen Rare Disease segment.
- Addition of ILUVIEN® and YUTIQ® will add approximately $105 million in revenues.
- Transaction expected to deliver high single-digit to low double-digit accretion in adjusted EPS.
Key Facts
- ANI to acquire Alimera for $5.50 per share in cash, aiming to strengthen Rare Disease segment.
- Addition of ILUVIEN® and YUTIQ® will add approximately $105 million in revenues.
- Transaction expected to deliver high single-digit to low double-digit accretion in adjusted EPS.